Thursday, July 9, 2026

biotech · Cervical Spinal Cord Injury · Spinal Cord Injury · LCTX

Lineage Cell Therapeutics

Lineage Cell Therapeutics is a biotech organization headquartered in Carlsbad, USA. It trades on NYSE under ticker LCTX. Primary therapeutic focus areas include Cervical Spinal Cord Injury, Spinal Cord Injury, Spinal Cor

Carlsbad, USA HQ
1990 Founded
35 Employees
Public company Type
LCTX · NYSE Ticker
Company details
Status
Public
HQ
Carlsbad, USA
Founded
1990
Employees
35
Programs
3
Drugs
0
Patents
0

Quick answer

Lineage Cell Therapeutics is a biotech organization headquartered in Carlsbad, USA. It trades on NYSE under ticker LCTX. Primary therapeutic focus areas include Cervical Spinal Cord Injury, Spinal Cord Injury, Spinal Cord Injury Cervical. NovaPharmaNews links 3 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 1 (2), phase 2 (1).

Company snapshot

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its proprietary cell-based therapy platform and associated development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally-differentiated human cells from its pluripotent and progenitor

  • 3 active pipeline program(s) linked via ClinicalTrials.gov.
  • 3 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Lineage Cell Therapeutics. Not investment advice.

Top assets

Lead pipeline drugs

  • AST-OPC1 Cervical Spinal Cord Injury
    Phase 2
  • GRNOPC1 Spinal Cord Injury
    Phase 1
  • OPC1 Spinal Cord Injury Cervical
    Phase 1

Active clinical programs

  • AST-OPC1 Cervical Spinal Cord Injury
    Phase 2
  • GRNOPC1 Spinal Cord Injury
    Phase 1
  • OPC1 Spinal Cord Injury Cervical
    Phase 1

Momentum

Proprietary activity score for Lineage Cell Therapeutics.

1 active signal

20 /100 +0 vs 30 days ago

Signal breakdown

  • Clinical trials 3 30d
  • Nova articles 0 30d
  • Patents filed 0 30d
  • FDA actions 0 30d
  • SEC filings 0 30d
  • Conference presentations 0 90d
  • Pipeline advances 0 30d

Recent activity

Latest pipeline, patent, and corporate events for Lineage Cell Therapeutics.

  1. Clinical update

    AST-OPC1 — Phase 2

  2. Clinical update

    GRNOPC1 — Phase 1

  3. Clinical update

    OPC1 — Phase 1

View all clinical trial activity →

Quick answers

Common questions about this sponsor — for analysts and search.

  • What is Lineage Cell Therapeutics?

    Lineage Cell Therapeutics is a biotech organization headquartered in Carlsbad, USA. It trades on NYSE under ticker LCTX. Primary therapeutic focus areas include Cervical Spinal Cord Injury, Spinal Cord Injury, Spinal Cord Injury Cervical. NovaPharmaNews links 3 clinical program(s

  • Is Lineage Cell Therapeutics publicly traded?

    Yes. Lineage Cell Therapeutics is listed with ticker LCTX on NYSE per SEC EDGAR records linked on this profile.

  • What drugs does Lineage Cell Therapeutics develop or market?

    No drug profiles are currently linked to Lineage Cell Therapeutics. Pipeline programs may still list investigational assets.

  • What are the latest developments for Lineage Cell Therapeutics?

    In the last 12 months our linked public records show 3 trial program update(s) and 0 US patent grant(s) tied to this profile.

  • What therapeutic areas does Lineage Cell Therapeutics focus on?

    Lineage Cell Therapeutics focuses on Cervical Spinal Cord Injury, Spinal Cord Injury, Spinal Cord Injury Cervical based on our analysis of their pipeline programs and drug development activities.

Therapeutic focus

Therapeutic area distribution

Pipeline concentration by therapeutic area from linked clinical programs.

Programs by therapeutic area

Others
6